Roche Renews Focus On Sequencing With Genia Acquisition
The deal, worth $125 million up front plus milestones, gives Roche a gateway into the emerging nanopore sequencing segment – the method is expected to “reduce the price of sequencing while increasing speed and sensitivity.”
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.